Claims for Patent: 3,987,200

Summary for Patent: 3,987,200

Title:	Method for increasing cardiac contractility
Abstract:	N-Mono or dihydroxyphenylalkyl dopamine derivatives and salts thereof are inotropic agents useful in a method for treatment of acutely depressed cardiac insufficiency.
Inventor(s):	Tuttle; Ronald R. (Indianapolis, IN), Mills; Jack (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	05/541,179
Patent Claims:	1. The method for increasing cardiac contractility in a warm-blooded mammal suffering from acutely depressed cardiac contractility which comprises administering to said mammal at a rate of between 0.5 and 10 micrograms per kilogram of body weight per minute a compound of the formula ##SPC5## wherein R and R.sub.1 are hydrogen or methyl; R.sub.2 and R.sub.3 are hydrogen or hydroxy, at least one of R.sub.2 and R.sub.3 being hydroxy; n is 1 or 2; subject to the limitation that when n is 2, R.sub.2 is hydrogen and R.sub.3 is hydroxy, one of R or R.sub.1 is hydrogen and the other is methyl; and the pharmaceutically acceptable acid addition salts thereof with mineral acids. 2. The method of claim 1 wherein the compound administered is a compound of the formula ##SPC6## wherein R and R.sub.1 are hydrogen or methyl; R.sub.2 and R.sub.3 are hydrogen or hydroxy, at least one of R.sub.2 and R.sub.3 being hydroxy; n is 1 or 2; subject to the limitation that when n is 2, R.sub.2 is hydrogen and R.sub.3 is hydroxy, one of R or R.sub.1 is hydrogen and the other is methyl; with the further limitations that when n is 2 and R.sub.2 and R.sub.3 are both hydroxy, then R.sub.1 is hydrogen, and when n is 1, R.sub.2 is hydrogen and R.sub.3 is hydroxy, then R and R.sub.1 are both hydrogen; and the pharmaceutically acceptable acid addition salts with mineral acids. 3. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-.beta.-phenethylam ine hydrochloride. 4. The method of claim 2 wherein the compound administered is levo-3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methyl-n-propyl]-.beta.-phenet hylamine hydrochloride. 5. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(3-hydroxyphenyl-n-propyl]-.beta.-phenethylamine hydrochloride. 6. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-n-propyl]-.alpha.-methyl-.beta.-phene thylamine hydrochloride. 7. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[2-(3,4-dihydroxyphenyl)ethyl]-.beta.-phenethylamine. 8. The method of claim 2 wherein the compound administered is 3,4-dihydroxy-N-[3-(3,4-dihydroxyphenyl)-n-propyl]-.beta.-phenethylamine hydrochloride.